RPL11: A Drug Target and Biomarker for Protein Synthesis (G6135)

Target Name: RPL11

NCBI ID: G6135

RPL11

RPL11: A Drug Target and Biomarker for Protein Synthesis

RPL11 (Ribosomal Protein L11) is a protein that is expressed in almost all eukaryotic cells and plays a critical role in protein synthesis. It is a large protein that contains multiple domains, including a supercoiled domain, a 尾-sheet, and a terminal hypervariable region (HVR).

RPL11 is a key regulator of protein synthesis and has been implicated in a number of cellular processes. It has been shown to regulate the size and composition of proteins, and is involved in the regulation of gene expression. It is also involved in the formation of the ribosome, which is the protein complex that reads the genetic code in DNA and synthesizes proteins.

Drug Targeting

Drug targeting is the process of using small molecules or antibodies to inhibit the activity of a specific protein and treat or diagnose diseases caused by the overactive or missing protein. RPL11 is a drug target due to its involvement in the regulation of protein synthesis and its role in the formation of the ribosome.

One of the main drug targets for RPL11 is the inhibition of its activity by small molecules such as rapamycin. Rapamycin is an immunosuppressant that inhibits the activity of the mTOR complex, which includes RPL11. The mTOR complex is involved in the regulation of cell growth, metabolism, and autophagy, and is a key regulator of protein synthesis. By inhibiting the activity of RPL11, rapamycin can prevent the regulation of protein synthesis and cell growth, which can lead to a variety of therapeutic effects.

Another potential drug target for RPL11 is the use of antibodies that recognize and label RPL11. This can be used to monitor the activity of RPL11 and to study its function in different cellular processes. Antibodies against RPL11 have been shown to be effective in inhibiting the activity of RPL11 and can be used to treat diseases caused by the overactive or missing protein.

Biomarker

RPL11 is also a biomarker that can be used to diagnose and monitor diseases caused by the overactive or missing protein. The levels of RPL11 can be used to assess the effectiveness of drugs that target RPL11, and to monitor the progression of diseases associated with RPL11 dysfunction.

Conclusion

RPL11 is a protein that plays a critical role in the regulation of protein synthesis and has been implicated in a number of cellular processes. Its activity can be inhibited by small molecules such as rapamycin, and its function can be monitored using antibodies that recognize and label RPL11. These results suggest that RPL11 is a promising drug target and a biomarker for a variety of diseases. Further research is needed to fully understand the role of RPL11 in cellular processes and to develop effective treatments.

Protein Name: Ribosomal Protein L11

Functions: Component of the ribosome, a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:32669547, PubMed:19191325). The small ribosomal subunit (SSU) binds messenger RNAs (mRNAs) and translates the encoded message by selecting cognate aminoacyl-transfer RNA (tRNA) molecules (PubMed:32669547, PubMed:19191325). The large subunit (LSU) contains the ribosomal catalytic site termed the peptidyl transferase center (PTC), which catalyzes the formation of peptide bonds, thereby polymerizing the amino acids delivered by tRNAs into a polypeptide chain (PubMed:32669547, PubMed:19191325). The nascent polypeptides leave the ribosome through a tunnel in the LSU and interact with protein factors that function in enzymatic processing, targeting, and the membrane insertion of nascent chains at the exit of the ribosomal tunnel (PubMed:32669547, PubMed:19191325). As part of the 5S RNP/5S ribonucleoprotein particle it is an essential component of the LSU, required for its formation and the maturation of rRNAs (PubMed:19061985, PubMed:12962325, PubMed:24120868). It also couples ribosome biogenesis to p53/TP53 activation. As part of the 5S RNP it accumulates in the nucleoplasm and inhibits MDM2, when ribosome biogenesis is perturbed, mediating the stabilization and the activation of TP53 (PubMed:24120868). Promotes nucleolar location of PML (By similarity)

The "RPL11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets